Mineralys Therapeutics (MLYS) Earnings Call Presentation

Explore-CKD Trial Results - Lorundrostat 25mg demonstrated a 9.3 mmHg absolute reduction in systolic blood pressure (SBP) at week 4[8, 19] - The placebo-adjusted change in systolic blood pressure was -7.5 mmHg (90% C.I -11.6, -3.4, p=0.002)[19] - A 31% reduction in spot Urine Albumin-to-Creatinine Ratio (UACR) was observed with lorundrostat (p < 0.0001)[8, 20] Safety Profile - The mean change in serum potassium was 0.5 mmol/L in lorundrostat treatment periods[27] - One subject (1.7%) discontinued due to potassium >6.5 mmol/L and low eGFR[27] - One subject (1.7%) discontinued due to low eGFR[28] Patient Demographics - The study population was 69% male with a mean age of 65 years[11] - 76% of participants had diabetes[11] - Baseline geometric mean spot urine UACR was 516 mg/g[12] - Mean systolic AOBP was 149 mmHg[13] Overall Conclusions - The Explore-CKD trial is the fourth positive clinical trial of lorundrostat in uHTN or rHTN[7] - Lorundrostat shows potential for aldosterone synthase inhibition in cardiorenal disorders[7] - The data demonstrates a consistent, clinically meaningful profile with the potential to benefit a spectrum of hypertension patients[39]